<DOC>
	<DOCNO>NCT00388011</DOCNO>
	<brief_summary>Study design evaluate efficacy safety Intranasal ( IN ) Morphine Nasal Spray ( MNS075 ) 3.75 mg , 7.5 mg , 15 mg , 30 mg , intravenous ( IV ) morphine 7.5 mg , IN placebo patient moderate severe post-surgical pain follow orthopedic surgery . After initial dosing , six ( 6 ) dos IN MNS075 7.5 mg 15 mg twenty-four ( 24 ) hour evaluate . The rescue dose remain .</brief_summary>
	<brief_title>Efficacy Safety Intranasal Morphine Pain After Bunion Surgery</brief_title>
	<detailed_description>Diagnosis Main Criteria Inclusion : Healthy adult patient ( 18 76 year old ) , score PS-1 PS-3 accord American Society Anesthesiologists Physical Status Classification System , require primary , unilateral , first metatarsal bunionectomy surgery alone ipsilateral hammertoe repair without additional collateral procedure .</detailed_description>
	<mesh_term>Hallux Valgus</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<criteria>Requires primary unilateral first metatarsal bunionectomy surgery alone ipsilateral hammertoe repair regional anesthesia . The patient require collateral orthopedic surgical procedure ipsilateral hammertoe repair may enrol study . 18 year age old Moderate severe pain within eight ( 8 ) hour follow completion require bunionectomy surgery Allergy shellfish Signs nasal congestion , nasal polyp , mucosal lesion nostril , postnasal drip etiology clinically significant nasal pathology may affect absorption study medication assessment safety . Chronic respiratory insufficiency treatment opioid analgesic contraindicate Additional Inclusion/Exclusion Criteria May Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Post surgical pain</keyword>
	<keyword>Bunionectomy</keyword>
	<keyword>Hammer Toe Syndrome</keyword>
	<keyword>Morphine</keyword>
</DOC>